PMID- 37822420 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240210 IS - 2325-9671 (Print) IS - 2325-9671 (Electronic) IS - 2325-9671 (Linking) VI - 11 IP - 10 DP - 2023 Oct TI - Long-Term Outcomes of Primary Hip Arthroscopy With Labral Repair for Femoroacetabular Impingement: Results at Minimum 9-Year Follow-up. PG - 23259671231204337 LID - 10.1177/23259671231204337 [doi] LID - 23259671231204337 AB - BACKGROUND: Hip arthroscopy continues to advance and become increasingly commonly performed. With the evolution of techniques and instrumentation, labral repair rather than debridement has emerged as the treatment of choice for labral pathology. There remains a lack of data on long-term outcomes after labral repair. PURPOSE: To (1) evaluate long-term patient-reported outcomes of primary hip arthroscopy with labral repair for femoroacetabular impingement, (2) report achievement rates of Patient Acceptable Symptom State (PASS) and minimal clinically important difference (MCID), and (3) investigate rates of reoperation and progression to total hip arthroplasty (THA). STUDY DESIGN: Case series; Level of evidence, 4. METHODS: Prospectively collected data were reviewed for patients who underwent primary hip arthroscopy with labral repair between 2010 and 2013. Patients' medical records were reviewed for demographic characteristics, intraoperative findings, reoperation, and progression to THA. Patients were assessed pre- and postoperatively using the following scales: visual analog scale (VAS) for pain; Tegner activity scale; modified Harris Hip Score (mHHS); 12-item International Hip Outcome Tool (iHOT-12); Hip Outcome Score-Activities of Daily Living (HOS-ADL); HOS-Sport-Specific Subscale (HOS-SSS); and Non-Arthritic Hip Score. Patients were also surveyed for satisfaction, subjective improvement, and level of function. RESULTS: A total of 32 patients (n = 24 women; n = 8 men) with a mean age of 27.7 years (range, 13.6-51 years) were evaluated for a mean of 9.4 years (range, 9-12.1 years). Patients achieved significant mean improvements in VAS pain at rest of 2 points, VAS pain with use of 1.9, mHHS of 19.9 points, iHOT-12 of 33.5 points, HOS-ADL of 17.4 points, and HOS-SSS of 29.5 points (P/=68%, the PASS achievement rates ranged from 39% to 65%, and the mean patient satisfaction was 8.1 on a 1 to 10 scale, with 10 denoting most satisfied. CONCLUSION: Patients demonstrated significant postoperative improvements in pain, mHHS, iHOT-12, HOS-ADL, and HOS-SSS scores at 9 years postoperatively. The all-cause reoperation rate was 34.4%, and 12.5% of patients progressed to THA. CI - (c) The Author(s) 2023. FAU - Wang, Allen S AU - Wang AS AD - Department of Orthopedic Surgery, Mayo Clinic, Rochester, Minnesota, USA. FAU - Lamba, Abhinav AU - Lamba A AD - Department of Orthopedic Surgery, Mayo Clinic, Rochester, Minnesota, USA. FAU - Okoroha, Kelechi R AU - Okoroha KR AD - Department of Orthopedic Surgery, Mayo Clinic, Rochester, Minnesota, USA. FAU - Levy, Bruce A AU - Levy BA AD - Department of Orthopedic Surgery, Mayo Clinic, Rochester, Minnesota, USA. FAU - Krych, Aaron J AU - Krych AJ AD - Department of Orthopedic Surgery, Mayo Clinic, Rochester, Minnesota, USA. FAU - Hevesi, Mario AU - Hevesi M AD - Department of Orthopedic Surgery, Mayo Clinic, Rochester, Minnesota, USA. LA - eng GR - T32 AR056950/AR/NIAMS NIH HHS/United States PT - Journal Article DEP - 20231009 PL - United States TA - Orthop J Sports Med JT - Orthopaedic journal of sports medicine JID - 101620522 PMC - PMC10563472 OTO - NOTNLM OT - femoroacetabular impingement OT - hip arthroscopy OT - impingement OT - minimally invasive COIS- One or more of the authors has declared the following potential conflict of interest or source of funding: Funding was provided by the Foderaro-Quattrone Musculoskeletal-Orthopaedic Surgery Research Innovation Fund. Partial funding was provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases for the Musculoskeletal Research Training Program (T32AR56950). K.R.O. has received grant support from Arthrex; education payments from Arthrex, Endo Pharmaceuticals, Pinnacle, and Smith & Nephew; nonconsulting fees from Smith & Nephew and Arthrex; consulting fees from Endo Pharmaceuticals and Smith & Nephew; and hospitality payments from Medical Device Business Services, Stryker, and Wright Medical. B.A.L. has received nonconsulting and consulting fees from Arthrex and Smith & Nephew; nonconsulting fees from Linvatec; royalties from Arthrex; and stock or stock options from COVR Medical. A.J.K. has received research support from Aesculap/B. Braun and DJO; consulting fees from Arthrex, JRF Ortho, and Responsive Arthroscopy; nonconsulting fees from Arthrex; royalties from Arthrex; and honoraria from JRF Ortho and MTF Biologics. M.H. has received education payments from Medwest Associates and Smith & Nephew and hospitality payments from Medical Device Business Services. AOSSM checks author disclosures against the Open Payments Database (OPD). AOSSM has not conducted an independent investigation on the OPD and disclaims any liability or responsibility relating thereto. Ethical approval for this study was obtained from the Mayo Clinic (No. PR08-002259-15). EDAT- 2023/10/12 06:43 MHDA- 2023/10/12 06:44 PMCR- 2023/10/09 CRDT- 2023/10/12 04:02 PHST- 2023/05/03 00:00 [received] PHST- 2023/05/19 00:00 [accepted] PHST- 2023/10/12 06:44 [medline] PHST- 2023/10/12 06:43 [pubmed] PHST- 2023/10/12 04:02 [entrez] PHST- 2023/10/09 00:00 [pmc-release] AID - 10.1177_23259671231204337 [pii] AID - 10.1177/23259671231204337 [doi] PST - epublish SO - Orthop J Sports Med. 2023 Oct 9;11(10):23259671231204337. doi: 10.1177/23259671231204337. eCollection 2023 Oct.